Nephrologie
Excellence in kidney disease research
Accelerate innovative treatments for kidney diseases. With deep expertise and a proven track record, we deliver comprehensive support for your nephrology clinical trials, ensuring efficient study execution and high-quality data.
Collaborate with renowned nephrologists
Collaborate with a respected board-certified nephrologist to ensure your trial design and execution are second to none.
Engage global regulatory and operational experts
Benefit from top-tier regulatory strategy and operational experts for precise, data-driven planning.
Leverage our strong nephrology network
Use our connections with nephrology sites, dialysis organizations and kidney patient advocacy groups for timely, diversity-focused recruitment.
Specific expertise for your next nephrology trial
- Benefit from focused training specific to each nephrology study type to address issues like proper 24-hour urine collections, renal biomarker development, PRO collection and central lab monitoring.
- Leverage deep experience in trial execution across top kidney disease indications such as chronic kidney disease, diabetic kidney disease, glomerular disease and lupus nephritis to understand site nuances and ensure successful trial execution for dialysis, rare kidney disease (e.g., glomerular disease) and common CKD (e.g., diabetic kidney disease).
- Harness the combined expertise of our Clinical Pharmacology Solutions and our Rare and Pediatric Disease colleagues, delivering renal impairment studies and bringing expertise to rare kidney diseases such as FSGS and IgAN.
Nephrology experience matters
In the last 5 years, we have supported:
Top indications
- Dialysis and End-stage kidney disease (ESKD)
- Glomerular disease
- Chronic kidney disease (CKD) and its complications
- Pediatric CKD and ESKD
- Studien zur Niereninsuffizienz
Our experts
Delivering nephrology leadership
Eine einzigartige Partnerschaft beginnt mit einem erfahrenen Team. Browse the bios of our featured team members.
Dr. Barbara S. Gillespie, MMS, FASN
Vice President & Therapeutic Strategy Leader
Vice President & Therapeutic Strategy Leader at Fortrea, Board Certified Nephrologist, Adjunct Professor at University of North Carolina, Division of Nephrology & Hypertension and past Associate Medical Director at local dialysis units.
Board of Directors (2018-2023) for the Kidney Health Initiative (a public-private collaboration between the FDA and the American Society of Nephrology). Co-chair of Steering Committee for APOL1 Kidney Disease; work group member (and publication co-author) for Endpoints in IgAN, FSGS, C3G, Peds IgAN and CVO Trial challenges in CKD patients. Steering Committee for NFK CKD Patient Registry (Patient Network) and serves on multiple Advisory Boards and Stakeholder Committees (e.g., NephCure and International Society of Glomerular Disease's PARASOL for FSGS Endpoints; PREPARE-NS for PROs; NKF Scientific Workshops for Renal Endpoints in Early CKD; Medical Ad Board for Regional NKF, NephCure MN Consensus Group, PCORI, SONG) and invited faculty speaker at many global nephrology conferences.
Collaborating with sponsors since 2006 on renal clinical development programs across 20+ indications in both CKD and End Stage Kidney Disease and associated complications
Gong Qing, MD
Associate Medical Director
Gong Qing, MD, ist Associate Medical Director der Abteilung Klinische Entwicklungsleistungen von Fortrea in Shanghai, China. Sie verfügt über mehr als 16 Jahre Erfahrung in der akademischen und klinischen Praxis und über 4 Jahre Erfahrung in der klinischen Entwicklungsforschung in der Früh- und Spätphase, darunter in der Onkologie und anderen Therapiebereichen. Ihre Branchenerfahrung umfasst globale Studien solider Tumore, einschließlich Brustkrebs, NSCLC und Bauchspeicheldrüsenkrebs, zur Entwicklung von Produkten für Biologics, gezielte Therapien und Chemotherapien. Vor Ihrer Karriere in der Branche war Dr. Gong als stellvertretende Chefärztin und seit 2018 in einem Pharmaunternehmen als medizinische Verantwortliche tätig. Sie hat sich unserem Unternehmen im März 2020 angeschlossen.
Evelyn Go, MD
Senior Medical Director
- Senior Medical Director at Fortrea. Board certified internist and nephrologist
- 15 years clinical experience as internist and renal physician including serving as in-house nephrologist at dialysis centers.
- Clinical trial industry related experience since 2009. Collaborating with sponsors serving as project medical lead and scientific advisor on various therapeutic indications including CKD and End Stage Kidney Disease, Lupus Nephritis, hemodialysis study and associated complications
Fortrea is an amazing partner for conducting this Phase III clinical trial. We achieved all the milestones planned, and this was only possible due to all the great collaboration between both companies. Fortrea was flexible when this was required and proactive on improving their processes.
Large Pharma
We achieved all the milestones planned
Choose an agile partner for your nephrology clinical trials
Once your trial is underway, our clinical trial management team ensures close communication and collaboration. Our highly flexible clinical platform for electronic patient-reported outcomes delivers high-quality data that keep you connected to your program's progress.
Let’s go
From Phase I to clinical pharmacology through Phase IV clinical trial management, patient access solutions and other enabling services, our partnerships with emerging and large biopharma alike drive healthcare innovation globally. Work with us and maximize the impact of your nephrology trial.
Erkenntnisse
Get the latest updates from our nephrology team
Development pathways and trial design for liver cirrhosis secondary to NASH
Download White Paper
Get Your Study Enrolled - Designing Your Impairment Protocol to Prevent Challenges
Webinar ansehen
Einzigartige Partnerschaften zur Erforschung seltener Nierenerkrankungen
Explore Fortrea's unique collaborative efforts in researching and addressing rare kidney diseases through advanced methodologies and patient-centric approaches.
Weiterlesen
SGLT2-Inhibitoren als nierenschützende Agenten für pädiatrische Patienten mit chronischen Nierenerkrankungen
Explore the benefits of SGLT2 inhibitors as renoprotective agents for pediatric patients. Fortrea's blog provides insights into diabetes medication and renal protection.
Weiterlesen
Unleashing the power of data sharing to transform the drug development landscape for kidney diseases
In 2016, Barbara Gillespie, MD, FASN, Vice President and Therapeutic Head of Nephrology at Fortrea, joined a workgroup with the Kidney Health Initiative (KHI) and U.S. FDA. T
Download Article
Anmeldung Ihrer Studie – Welche Angaben Sie in dem Protokoll zu Ihrer Studie zu Niereninsuffizienz vermeiden müssen, um eine Verlangsamung der Anwerbung zu verhindern
Webinar ansehen
Dr. Gillespie goes to Capitol Hill to advocate for rare kidney disease
Dr. Barbara Gillespie, Vice President & Therapeutic Strategy Leader at Fortrea, recently participated in “Rare Kidneys on the Hill Day” on July 25th, joining patients, caregivers, physicians and researchers on Capitol Hill to speak with members of Congress and raise awareness about rare kidney disease (RKD).
Weiterlesen